The Williams return is still a rule story before it is a fairy tale. The paper's June 17 account of the wild-card rule and GLP-1 line said the comeback had to stay attached to eligibility and anti-doping documents. June 18 makes that attachment sharper.

Yahoo's USA Today report says Serena Williams will play doubles at the HSBC Championships, a Wimbledon warmup, through a wild card [1]. It notes she had not played since the 2022 U.S. Open, rejoined the International Tennis Integrity Agency testing pool, and was reinstated February 22 after the six-month eligibility period [1]. That is the entry mechanism. It may be generous, commercial, sentimental, or strategic. It is still a mechanism.

The GLP-1 branch needs the same discipline. Yahoo reports that Williams had said she lost 31 pounds after using a GLP-1 drug and that the treatment helped relieve joint pain [1]. That fact explains why suspicion travels. It does not prove a violation.

WADA's prohibited-list page is the governing reference point for banned substances and methods [2]. The 2026 monitoring-program PDF is separate. It says WADA monitors substances that are not on the Prohibited List but that it wishes to monitor for potential misuse patterns, and it places markers of semaglutide and tirzepatide in that monitoring program in and out of competition [3]. Monitoring is not the same as prohibition.

WADA also hosts a scientific-research resource on analysis of GLP-1 receptor agonists such as semaglutide and liraglutide from blood and dried blood spots [4]. That shows anti-doping authorities are studying detection and use. It still does not, by itself, move the compounds into the prohibited category.

The testing-pool fact is the other guardrail. Yahoo's account says Williams rejoined the International Tennis Integrity Agency testing pool and completed the six-month eligibility period before the wild-card return. [1] That does not make the comeback beyond criticism, but it moves the debate from insinuation to the published pathway that returning players must use.

MSM likes the comeback because Serena and Wimbledon make a clean human-interest package. X likes the suspicion because modern sports discourse treats body change, age, recovery, and medication as one insinuation. The correct article refuses both shortcuts.

Argue the wild card if you want to argue the wild card. Ask whether discretionary entries should go to legends, local players, or qualifiers. Argue GLP-1 policy if WADA changes the list or another authority supplies a case. Until then, the return sits inside the published rules that govern it.

-- AMARA OKONKWO, Lagos